This excerpt taken from the ELN 20-F filed Feb 26, 2009.
Advancing Neuroscience, Growing the Business
In 2008, we continued to fulfill our mission of making significant scientific advancements in neuroscience while continuing overall growth of the business.
Our operations are organized into two business units: Biopharmaceuticals, which engages in research, development and commercial activities primarily in neuroscience, autoimmune and severe chronic pain, and Elan Drug Technologies (EDT), which focuses on the specialty pharmaceutical industry, including specialized drug delivery and manufacturing.
We made significant research and development progress, particularly in the clinical advancement of our Alzheimers disease programs. Our Alzheimers platform is marked by three distinct approaches to modify the beta amyloid cascade, a complex process thought to underlie Alzheimers disease.
Our deep scientific expertise is also evident in our work in Parkinsons disease, where our scientists continue to build on their work based on modified forms of alpha-synuclein found in human Parkinsons disease brain tissue, and with parkin, a brain protein linked to the disease.
We continued to grow the value of Tysabri as an important therapeutic approach to multiple indications. Tysabri is an approved therapy for relapsing forms of multiple sclerosis (MS) in the United States and for relapsing-remitting MS in the European Union. Tysabri sales grew significantly in 2008, reflecting strong patient demand across global markets.
Tysabri is also approved in the United States for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohns disease (CD), with evidence of inflammation, who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of tumor necrosis factor alpha (TNF-alpha).
The medical and scientific opportunity represented by Elans biopharmaceutical pipeline remains significant.
Our EDT business is the oldest, independent drug delivery firm in the industry. As a leader in the business, we have contributed to over $15 billion of in-market sales for our clients over our history. An established, profitable specialty pharmaceutical business unit of Elan, EDT has been applying its skills and knowledge to enhance the performance of dozens of drugs that have subsequently been marketed worldwide. Today, products enabled by EDT technologies are used by millions of patients each day.